PE20041063A1 - Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico - Google Patents

Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico

Info

Publication number
PE20041063A1
PE20041063A1 PE2004000262A PE2004000262A PE20041063A1 PE 20041063 A1 PE20041063 A1 PE 20041063A1 PE 2004000262 A PE2004000262 A PE 2004000262A PE 2004000262 A PE2004000262 A PE 2004000262A PE 20041063 A1 PE20041063 A1 PE 20041063A1
Authority
PE
Peru
Prior art keywords
formulation
chloro
methyl
fluoroaniline
pharmaceutical composition
Prior art date
Application number
PE2004000262A
Other languages
English (en)
Inventor
Patrick Forenzo
Maha Y Khaled
Barbara Wang
Joseph Lawrence Zielinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20041063(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20041063A1 publication Critical patent/PE20041063A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMULACION ORAL LIQUIDA QUE COMPRENDE a) AGUA; b) ACIDO 5-METIL-2-(2'-CLORO-6'-FLUOROANILINO)FENILACETICO Y c) UN AGENTE DE SUSPENSION SELECCIONADO DE CELULOSA MICROCRISTALINA, CARBOXIMETILCELULOSA DE SODIO, GOMA XANTAN, ENTRE OTROS; DONDE EL pH DE LA FORMULACION ES DE 4.3 A 5.5. LA FORMULACION COMPRENDE ADEMAS UN HUMECTANTE SELECCIONADO DE POLISORBATO 80, POLAXAMEROS, ACEITE DE RICINO, ENTRE OTROS; UN AGENTE ANTIESPUMANTE; UN CONSERVADOR. LA FORMULACION COMPRENDE UN SISTEMA REGULADOR DE pH QUE COMPRENDE CITRATO DE METAL ALCALINO CON ACIDO CITRICO, SALES DE ACETATO, SALES DE SUCCINATO ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION
PE2004000262A 2003-03-12 2004-03-10 Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico PE20041063A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45414503P 2003-03-12 2003-03-12

Publications (1)

Publication Number Publication Date
PE20041063A1 true PE20041063A1 (es) 2005-03-07

Family

ID=32990870

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000262A PE20041063A1 (es) 2003-03-12 2004-03-10 Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico

Country Status (30)

Country Link
US (2) US20060094787A1 (es)
EP (1) EP1603550B1 (es)
JP (1) JP4580921B2 (es)
KR (1) KR20050109077A (es)
CN (1) CN100345536C (es)
AR (1) AR043536A1 (es)
AT (1) ATE418332T1 (es)
AU (1) AU2004218921B2 (es)
BR (1) BRPI0408270A (es)
CA (1) CA2518393A1 (es)
CL (1) CL2004000496A1 (es)
DE (1) DE602004018622D1 (es)
EC (1) ECSP055998A (es)
ES (1) ES2318277T3 (es)
HK (1) HK1086492A1 (es)
HR (1) HRP20050787A2 (es)
IL (1) IL170518A (es)
IS (1) IS2658B (es)
MA (1) MA27670A1 (es)
MX (1) MXPA05009686A (es)
MY (1) MY139455A (es)
NO (1) NO20054662L (es)
NZ (1) NZ542218A (es)
PE (1) PE20041063A1 (es)
PT (1) PT1603550E (es)
RU (1) RU2363462C2 (es)
TN (1) TNSN05222A1 (es)
TW (1) TWI327913B (es)
WO (1) WO2004080451A1 (es)
ZA (1) ZA200506750B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2541265A1 (en) * 2003-10-08 2005-04-28 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
KR100900915B1 (ko) * 2007-05-07 2009-06-05 이연제약주식회사 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
BRPI0820198A2 (pt) * 2007-11-12 2019-09-24 Novartis Ag composições farmacêuticas
EP2926810A1 (en) * 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical formulations of loxoprofen
CA3027434A1 (en) 2016-06-16 2017-12-21 Cutispharma, Inc. Composition and method for proton pump inhibitor suspension
CN109922801B (zh) 2016-09-09 2023-07-18 库蒂斯制药公司 甲硝唑和巴氯芬的混悬剂和稀释剂
EP3655418A4 (en) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. METHOD OF TREATMENT OF GLIOBLASTOMA
US11628144B2 (en) 2017-09-29 2023-04-18 Triact Therapeutics, Inc. Iniparib formulations and uses thereof
US10751333B1 (en) * 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5840768A (en) * 1997-06-04 1998-11-24 Fmc Corporation MCC: alginate pharmaceutical suspensions
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
BR0306726A (pt) * 2002-01-07 2004-12-21 Pharmacia Corp Mistura de fármacos com melhor taxa de dissolução
AU2003223491A1 (en) * 2002-04-05 2003-10-27 Nitromed, Inc. Nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
MA27670A1 (fr) 2005-12-01
ZA200506750B (en) 2007-02-28
RU2005131310A (ru) 2006-05-10
TWI327913B (en) 2010-08-01
IL170518A (en) 2010-11-30
US20090048344A1 (en) 2009-02-19
MXPA05009686A (es) 2005-10-20
JP2006519811A (ja) 2006-08-31
TNSN05222A1 (en) 2007-06-11
TW200505429A (en) 2005-02-16
KR20050109077A (ko) 2005-11-17
NZ542218A (en) 2009-01-31
US20060094787A1 (en) 2006-05-04
NO20054662L (no) 2005-12-05
ATE418332T1 (de) 2009-01-15
ES2318277T3 (es) 2009-05-01
ECSP055998A (es) 2006-01-27
CN100345536C (zh) 2007-10-31
IS2658B (is) 2010-08-15
EP1603550B1 (en) 2008-12-24
BRPI0408270A (pt) 2006-03-07
AR043536A1 (es) 2005-08-03
DE602004018622D1 (de) 2009-02-05
WO2004080451A1 (en) 2004-09-23
AU2004218921A1 (en) 2004-09-23
HK1086492A1 (en) 2006-09-22
HRP20050787A2 (en) 2006-12-31
CN1756541A (zh) 2006-04-05
AU2004218921B2 (en) 2007-05-17
EP1603550A1 (en) 2005-12-14
IS8049A (is) 2005-09-28
CL2004000496A1 (es) 2005-01-14
PT1603550E (pt) 2009-03-20
NO20054662D0 (no) 2005-10-11
MY139455A (en) 2009-10-30
CA2518393A1 (en) 2004-09-23
JP4580921B2 (ja) 2010-11-17
RU2363462C2 (ru) 2009-08-10

Similar Documents

Publication Publication Date Title
PE20041063A1 (es) Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico
AR102101A2 (es) Formulación y método de complejo de aripiprazol
HRP20170677T1 (hr) Farmaceutski sastav za kontrolirano otpuštanje koji sadrži ester fumarne kiseline
DK1073415T3 (da) Gelerbare farmaceutiske sammensætninger
ES2102919T3 (es) Composicion acida a base de vesiculas lipidicas y su utilizacion en aplicacion topica
NO20002991D0 (no) Farmasøytiske sammensetninger som inneholder en omega-3- fettsyreolje
BE901359A (fr) Composition pharmaceutique a absorption reglee.
AR018526A1 (es) COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED
RS51579B (sr) Preparati insulina koji ne sadrže cink ili sadrže male količine cinka i koji imaju poboljšanu stabilnost
DE602004023106D1 (de) Pharmazeutische zusammensetzung mit prostaglandin
NZ592647A (en) Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
ES2720954T3 (es) Formulaciones estabilizadas de estatina
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
NO20010863L (no) Nye orale formuleringer for 5-HT4-agonister eller - antagonister
PE20130180A1 (es) Soluciones farmaceuticas orales que comprenden telbivudina
JP4880813B2 (ja) 外用消炎鎮痛剤組成物
DE60004191D1 (de) Gelöste pharmazeutische zusammensetzung für die parenterale verabreichung
CL2012001545A1 (es) Composiciones farmacéuticas acuosas que comprende un éster de un prostanoide, un ácido carboxílicoentre 1,2,1,6% de fosfato dibásico de sodio, cloruro de sodio, un agente de solubilización, y el resto de agua, con un ph va de 4 a 8; uso en desordenes oculares como glaucoma, retinopatia diabetica, uveitis, entre otras.
KR910009253A (ko) 경구용 액제
ES2052075T3 (es) Composicion farmaceutica liquida para derivados de piperidinoalcanol.
TH77904A (th) สารผสมทางเภสัชกรรม
JPS57102817A (en) Antiphlogistic ophthalmologic agent
TH77904B (th) สารผสมทางเภสัชกรรม
KR920703501A (ko) 세바스산 및 그 유도체의 장 경우 영양 및 비경구적 영양에서의 용도 및 이들 화합물을 함유한 의약 조성물
ES2189639B1 (es) Composicion acuosa que contiene acido acetilsalicilico.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed